Corcept sinks after judge rules for Teva in Korlym patent case

Teva Pharmaceuticals (TEVA) won a patent infringement lawsuit against Corcept Therapeutics (CORT) on Friday relating to Concept’s Cushing syndrome treatment Korlym. Corcept “has not demonstrated that there is a likelihood of direct infringement of the asserted claims in the future because it has not established that physicians are likely to coadminister mifepristone with a strong CYP3A inhibitor at an infringing sequence and/or dosage now or in the future,” Judge Renee Marie Bumb wrote in an opinion late Friday. “Indeed, Corcept failed to introduce credible record evidence that anyone has ever previously infringed the asserted claims,” according to the judge. Shares of Corcept Therapeutics are down 33% to $21.75 in premarket trading.